RxDoctor Payments Data

Fidelis Pe Benito

Psychiatric/Mental Health · Virginia Beach, VANPI 1689952871

Payments from drug & device makers

$534in general payments, 2019–2025

Across 25 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$147
  • Otsuka America Pharmaceutical, Inc.$139
  • Takeda Pharmaceuticals U.S.A., Inc.$58
  • Lundbeck LLC$51
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$40
  • Collegium Pharmaceutical, Inc.$24
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$534100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$534 in reported general payments places this provider in the 50th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$10,391
Medicare patients
37
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole13$21,798
TrintellixVortioxetine Hydrobromide18$13,069
Oxcarbazepine21$9,995
VyvanseLisdexamfetamine Dimesylate21$7,766
Lurasidone Hcl20$6,810
Aripiprazole42$4,575
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl98$3,360
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$3,122
Divalproex Sodium ErDivalproex Sodium17$1,819
Bupropion XlBupropion Hcl72$1,494
Methylphenidate Hcl54$1,421
Prazosin Hcl51$1,252
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine30$1,066
Olanzapine52$1,054
Clonazepam63$1,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$139$21,79813 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$58$20,83539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →